Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) Net Margin (2016 - 2017)

Historic Net Margin for Soleno Therapeutics (SLNO) over the last 5 years, with Q2 2017 value amounting to 91300.0%.

  • Soleno Therapeutics' Net Margin fell 340000000.0% to 91300.0% in Q2 2017 from the same period last year, while for Mar 2018 it was 275100.0%, marking a year-over-year decrease of 2738494300.0%. This contributed to the annual value of 76125.54% for FY2024, which is N/A changed from last year.
  • According to the latest figures from Q2 2017, Soleno Therapeutics' Net Margin is 91300.0%, which was down 340000000.0% from 317.74% recorded in Q1 2017.
  • Over the past 5 years, Soleno Therapeutics' Net Margin peaked at 295.07% during Q2 2014, and registered a low of 91300.0% during Q2 2017.
  • Its 5-year average for Net Margin is 11207.89%, with a median of 953.69% in 2016.
  • Over the last 5 years, Soleno Therapeutics' Net Margin had its largest YoY gain of 100781300bps in 2016, and its largest YoY loss of -541618600bps in 2016.
  • Quarter analysis of 5 years shows Soleno Therapeutics' Net Margin stood at 273.91% in 2013, then tumbled by -34bps to 179.54% in 2014, then crashed by -756bps to 1178.0% in 2015, then increased by 22bps to 920.89% in 2016, then crashed by -9814bps to 91300.0% in 2017.
  • Its Net Margin stands at 91300.0% for Q2 2017, versus 317.74% for Q1 2017 and 920.89% for Q4 2016.